Treatment of Cervical Cancer Stage IIB

Primary Treatment Approach

The National Comprehensive Cancer Network recommends concurrent cisplatin-based chemoradiation as the definitive treatment of choice for stage IIB cervical cancer, consisting of external-beam pelvic radiation therapy with concurrent platinum-containing chemotherapy followed by intracavitary brachytherapy 1, 2
Stage IIB cervical cancer is classified as locally advanced disease and requires definitive chemoradiation rather than primary surgery, with a Category 1 recommendation for concurrent chemoradiation with cisplatin-based chemotherapy 1, 3, 2

The established standard of care is concurrent chemoradiation with cisplatin-based chemotherapy, which produces a 30-50% reduction in risk of death compared to radiation therapy alone, based on five landmark randomized controlled trials 1
The treatment consists of external-beam pelvic radiation therapy with concurrent platinum-containing chemotherapy 1, 4
Intracavitary brachytherapy is used to achieve a total point A dose of 75-80 Gy 5, 6
Concurrent chemotherapy is administered during external-beam radiation, but not during brachytherapy 6, 1

Weekly cisplatin is the preferred concurrent chemotherapy regimen during radiation therapy 4
Alternative acceptable regimens include carboplatin, which is preferred if cisplatin is intolerant, and cisplatin plus 5-fluorouracil every 3-4 weeks, though the latter is more toxic than single-agent cisplatin 4, 6, 1
Single-agent cisplatin produces comparable survival outcomes to combination regimens with lower toxicity, making it the preferred choice for most patients 6, 1

A comprehensive staging workup is essential before initiating treatment, including a PET-CT scan to assess nodal involvement and rule out distant metastases 3, 2, 4
An MRI is used to evaluate disease extent, particularly high endocervical involvement 3, 2
Assessment of pelvic and para-aortic lymph node status is necessary to determine radiation field extent 3, 2, 4

For patients without nodal disease or disease limited to the pelvis only, pelvic EBRT with concurrent platinum-containing chemotherapy plus brachytherapy is recommended (Category 1) 4
For patients with positive para-aortic lymph nodes, extended-field EBRT to include the para-aortic region with concurrent platinum-containing chemotherapy plus brachytherapy is recommended 4

A meta-analysis demonstrates a 6% improvement in 5-year survival with concurrent chemoradiation over radiation alone (hazard ratio 0.81, P<0.001) 1
Long-term follow-up confirms a sustained survival benefit with concurrent chemoradiation 1

Acute hematological and gastrointestinal toxicity is significantly increased with chemoradiation compared to radiation alone, requiring close monitoring 6, 1
Vaginal dilators are strongly recommended after pelvic radiation to prevent vaginal stenosis and preserve sexual function 7

Radical hysterectomy should not be performed for stage IIB disease, as this stage involves parametrial extension making surgery inappropriate as primary treatment 1, 3, 2
Systemic consolidation chemotherapy after chemoradiation should not be used outside clinical trials, as this approach lacks proven benefit 6, 1
Brachytherapy should not be omitted, as it is an essential component achieving adequate central tumor dose 5, 6
Chemotherapy should be given during external-beam radiation, not during brachytherapy 6, 1

Surgical staging (extraperitoneal or laparoscopic lymph node dissection) is an option to better define nodal involvement and guide radiation field design, though not routinely required 3, 2

Five-year survival rates with concurrent chemoradiation for stage IIB disease are significantly improved compared to historical radiation-alone outcomes, with the survival benefit primarily resulting from improved local control 1